Stock listing
Lang & Schwarz:A2AMY9 Pulse Biosciences, Inc Aktie
German listing (Lang & Schwarz) of Pulse Biosciences, Inc · home listing NASDAQ:PLSE
Follow Pulse Biosciences, Inc into a list and get an email when it puts out news.
Home listing price · NASDAQ:PLSE
$45.55 USD -0.28 (-0.6%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PLSE
- Day range
- $43.84 – $46.00 USDNov 20, 2026
- Volume
- 466,798 sharesNov 20, 2026
- Market cap
- $3.35B USDAt the close on Nov 20, 2026 · price × 73.55M shares outstanding
- 52-week range
- $12.70 – $58.94 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $25.81M USDMedian day 450,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PLSE · Home | $45.55 USD | -0.28 (-0.6%) | 466,798 | $44.01 | $46.00 | $43.84 | $45.83 | Close on Nov 20, 2026 |
| Frankfurt:6L8 | €41.40 EUR | +0.40 (+1.0%) | — | €39.80 | €41.40 | €39.80 | €41.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PLSE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $45.55 | -0.28 | -0.6% | $44.01 | $46.00 | $43.84 | 466,798 | |
| $45.83 | +0.99 | +2.2% | $44.36 | $46.46 | $43.27 | 331,732 | |
| $44.84 | -1.52 | -3.3% | $46.16 | $46.29 | $43.14 | 628,284 | |
| $46.36 | -4.08 | -8.1% | $49.53 | $51.56 | $46.03 | 487,183 | |
| $50.44 | -1.81 | -3.5% | $52.53 | $54.25 | $50.23 | 590,639 | |
| $52.25 | -4.73 | -8.3% | $56.59 | $56.81 | $52.10 | 355,968 | |
| $56.98 | +1.86 | +3.4% | $55.36 | $57.07 | $53.97 | 357,535 | |
| $55.12 | -3.05 | -5.2% | $58.00 | $58.00 | $51.85 | 496,091 | |
| $58.17 | +4.88 | +9.2% | $53.36 | $58.94 | $53.36 | 534,487 | |
| $53.29 | +0.22 | +0.4% | $56.87 | $56.87 | $50.31 | 428,196 | |
| $53.07 | -3.99 | -7.0% | $56.01 | $57.72 | $50.80 | 534,198 | |
| $57.06 | +4.86 | +9.3% | $52.96 | $58.17 | $52.86 | 499,335 | |
| $52.20 | -0.70 | -1.3% | $53.42 | $55.20 | $51.64 | 386,074 | |
| $52.90 | +0.66 | +1.3% | $52.40 | $53.85 | $51.32 | 249,693 | |
| $52.24 | -3.24 | -5.8% | $54.33 | $54.70 | $51.39 | 466,442 | |
| $55.48 | +1.81 | +3.4% | $53.74 | $56.51 | $53.74 | 344,676 | |
| $53.67 | +0.47 | +0.9% | $53.12 | $54.73 | $52.76 | 279,982 | |
| $53.20 | +0.54 | +1.0% | $53.42 | $53.77 | $52.49 | 328,950 | |
| $52.66 | -0.36 | -0.7% | $52.75 | $53.60 | $52.07 | 282,470 | |
| $53.02 | +0.34 | +0.6% | $52.44 | $55.00 | $51.47 | 453,000 | |
| $52.68 | +1.37 | +2.7% | $50.92 | $53.67 | $50.00 | 421,400 | |
| $51.31 | +0.47 | +0.9% | $51.16 | $52.03 | $50.07 | 315,600 | |
| $50.84 | +3.29 | +6.9% | $47.25 | $52.33 | $47.25 | 385,900 | |
| $47.55 | +3.12 | +7.0% | $44.58 | $48.12 | $44.58 | 342,500 | |
| $44.43 | -1.16 | -2.5% | $45.49 | $46.67 | $43.32 | 327,400 | |
| $45.59 | -0.73 | -1.6% | $45.13 | $46.67 | $43.96 | 425,600 | |
| $46.32 | -2.22 | -4.6% | $47.60 | $48.97 | $44.80 | 440,300 | |
| $48.54 | -3.91 | -7.5% | $53.02 | $53.21 | $48.01 | 455,500 | |
| $52.45 | -1.36 | -2.5% | $53.53 | $53.98 | $50.15 | 434,400 | |
| $53.81 | +3.83 | +7.7% | $49.98 | $53.97 | $49.98 | 365,800 | |
| $49.98 | +0.89 | +1.8% | $48.90 | $50.32 | $47.31 | 315,600 | |
| $49.09 | -0.66 | -1.3% | $49.11 | $49.93 | $48.13 | 409,500 | |
| $49.75 | -0.75 | -1.5% | $51.26 | $51.26 | $48.62 | 421,400 | |
| $50.50 | +2.60 | +5.4% | $47.89 | $50.99 | $47.47 | 433,400 | |
| $47.90 | -1.93 | -3.9% | $50.13 | $50.71 | $47.75 | 519,100 | |
| $49.83 | -0.09 | -0.2% | $49.49 | $51.56 | $49.12 | 450,300 | |
| $49.92 | -0.97 | -1.9% | $51.18 | $51.27 | $49.17 | 604,600 | |
| $50.89 | -1.43 | -2.7% | $52.24 | $52.74 | $48.92 | 516,900 | |
| $52.32 | +0.69 | +1.3% | $51.63 | $53.60 | $51.14 | 374,400 | |
| $51.63 | -0.20 | -0.4% | $52.17 | $54.05 | $50.80 | 664,000 | |
| $51.83 | -0.15 | -0.3% | $52.18 | $53.61 | $51.62 | 666,900 | |
| $51.98 | -0.71 | -1.3% | $53.75 | $56.74 | $51.87 | 550,600 | |
| $52.69 | -0.62 | -1.2% | $53.23 | $53.79 | $52.49 | 372,200 | |
| $53.31 | -0.56 | -1.0% | $53.97 | $54.81 | $51.74 | 382,200 | |
| $53.87 | +3.26 | +6.4% | $50.61 | $54.29 | $50.25 | 867,500 | |
| $50.61 | +1.00 | +2.0% | $49.46 | $53.55 | $49.01 | 571,900 | |
| $49.61 | -5.59 | -10.1% | $52.55 | $54.24 | $48.61 | 1,036,200 | |
| $55.20 | +0.99 | +1.8% | $54.42 | $56.61 | $53.51 | 472,200 | |
| $54.21 | +1.10 | +2.1% | $52.30 | $55.78 | $51.60 | 505,800 | |
| $53.11 | -1.32 | -2.4% | $54.50 | $56.61 | $50.32 | 664,300 | |
| $54.43 | +1.46 | +2.8% | $52.18 | $57.94 | $51.30 | 915,500 | |
| $52.97 | +4.18 | +8.6% | $49.76 | $58.90 | $48.43 | 1,560,400 | |
| $48.79 | -4.45 | -8.4% | $52.93 | $53.11 | $47.70 | 769,300 | |
| $53.24 | -1.47 | -2.7% | $53.68 | $54.75 | $52.75 | 515,200 | |
| $54.71 | +2.03 | +3.9% | $53.79 | $55.37 | $53.11 | 702,800 | |
| $52.68 | +0.59 | +1.1% | $52.14 | $53.57 | $51.45 | 977,800 | |
| $52.09 | +1.76 | +3.5% | $49.93 | $54.39 | $49.16 | 1,132,900 | |
| $50.33 | +2.76 | +5.8% | $48.02 | $50.61 | $47.57 | 657,300 | |
| $47.57 | -0.99 | -2.0% | $48.06 | $49.00 | $47.01 | 262,700 | |
| $48.56 | +0.46 | +1.0% | $47.73 | $49.95 | $47.55 | 260,100 | |
| $48.10 | -0.90 | -1.8% | $49.00 | $49.74 | $47.93 | 270,100 | |
| $49.00 | -0.13 | -0.3% | $49.73 | $50.90 | $47.65 | 366,678 | |
| $49.13 | -1.29 | -2.6% | $50.34 | $50.34 | $46.34 | 345,885 | |
| $50.42 | +2.57 | +5.4% | $47.47 | $50.71 | $47.47 | 452,800 | |
| $47.85 | +0.83 | +1.8% | $46.76 | $48.58 | $46.64 | 238,600 |
- Ticker
- Lang & Schwarz:A2AMY9
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 20, 2026
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest earnings call · Nov 5, 2026
Pulse Biosciences (NASDAQ:PLSE) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 6, 2026
Q2 2026 Earnings Presentation
Earnings · 15 slides
Latest news
Pulse Biosciences to Present at Piper Sandler 38th Annual Healthcare Conference
Nov 19, 2026
Closed $45.55 (-0.6%) on Nov 20, 2026
Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting
Nov 6, 2026
Closed $53.29 (+0.4%) on Nov 6, 2026
Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results
Nov 5, 2026
Closed $53.29 (+0.4%) on Nov 6, 2026
Pulse Biosciences to Present at Stifel 2026 Healthcare Conference
Oct 29, 2026
Closed $55.48 (+3.4%) on Oct 29, 2026
Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026
Oct 22, 2026
Closed $53.02 (+0.6%) on Oct 23, 2026
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Oct 14, 2026
Closed $46.32 (-4.6%) on Oct 14, 2026
Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
Oct 8, 2026
Closed $49.98 (+1.8%) on Oct 8, 2026
Pulse Biosciences, Inc on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 43 in the last 12 months · 198 in all · newest Nov 20, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest Nov 5, 2026
- Decks
- 11 decks · latest Aug 6, 2026
Where Pulse Biosciences, Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PLSE · Home listing | NASDAQ | United States | USD |
| gettex:6L8 | gettex | Germany | EUR |
| LS Exchange:A2AMY9 | LS Exchange | Germany | EUR |
| BOATS:PLSE | BOATS | United States | USD |
| Lang & Schwarz:A2AMY9 · This page | Lang & Schwarz | Germany | EUR |
| Frankfurt:6L8 | Frankfurt | Germany | EUR |
| Tradegate:6L8 | Tradegate | Germany | EUR |
| Dusseldorf:6L8 | Dusseldorf | Germany | EUR |
| Munich:6L8 | Munich | Germany | EUR |
| Stuttgart:6L8 | Stuttgart | Germany | EUR |
| Hamburg:6L8 | Hamburg | Germany | EUR |
| Hanover:6L8 | Hanover | Germany | EUR |
| Xetra:6L8 | Xetra | Germany | EUR |
Valuation
EV/sales 2,120× against a median of 3.6×: 10th lowest of 11 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $3.17B USD
- P/E
- Loss
- EV/sales
- 2,120×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 18.3×
- Gross margin
- 9.4%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.54
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Pulse Biosciences, Inc · NASDAQ:PLSE | US$3.35B | US$3.17B | n/a | 2,120× | n/a | 18.3× | n/a | 0.0× | 1.54 |
| IMEIK Technology Development Co., Ltd. Class A · SZSE:300896 | US$3.67B | US$3.13B | 24.8× | 9.0× | n/a | 3.1× | 42.4% | 0.0× | n/a |
| Envista Holdings Corporation · NYSE:NVST | US$3.67B | US$3.94B | 5.8× | 1.4× | 4.7× | 1.2× | 22.0% | 0.5× | 1.18 |
| Shandong Weigao Blood Purification Products Co., Ltd. Class A · SSE:603014 | US$3.53B | US$2.97B | 23.4× | 3.7× | n/a | 2.2× | 18.6% | 0.0× | n/a |
| Axogen, Inc. · NASDAQ:AXGN | US$3.33B | US$2.98B | n/a | 11.2× | n/a | 6.7× | −12.0% | 0.0× | 0.98 |
| Zhende Medical Co., Ltd. Class A · SSE:603301 | US$3.23B | US$3.13B | 73.1× | 4.5× | n/a | 3.8× | 6.3% | 0.1× | n/a |
| Lepu Medical Technology (Beijing) Co., Ltd. Class A · SZSE:300003 | US$3.09B | US$3.03B | 31.4× | 3.3× | n/a | 1.3× | 10.7% | 0.2× | n/a |
| Carl Zeiss Meditec AG · XETR:AFX | US$3.06B | US$3.06B | 23.9× | 1.1× | n/a | 1.3× | 4.4% | 0.0× | n/a |
| Imricor Medical Systems, Inc. · ASX:IMR | US$2.99B | US$2.96B | n/a | 9,790× | n/a | 103× | n/a | 1.2× | n/a |
| TransMedics Group, Inc. · NASDAQ:TMDX | US$2.96B | US$2.52B | 20.5× | 3.5× | 19.8× | 5.4× | 19.9% | 0.1× | 1.31 |
| Ambu A/S Class B · OMXCOP:AMBU_B | US$2.92B | US$2.92B | 30.9× | 3.1× | 15.9× | 3.2× | 9.9% | 0.1× | n/a |
| Median of the others | US$3.16B | US$3.00B | 24.4× | 3.6× | 15.9× | 3.2× | 10.7% | 0.1× | 1.18 |
Forecasts
5 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 67.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.05 · 3 analysts
- Revenue, year to Dec 2026
- 1.77M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Kevin Danahy | President and Chief Executive Officer |
| Liane Teplitsky | Chief Operating Officer |
| David Kenigsberg | Chief Medical Officer of Electrophysiology |
| Niv Ad | Chief Science Officer, Cardiac Surgery |
Board
| Director | Role |
|---|---|
| Maria Sainz | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Pulse Biosciences (NASDAQ:PLSE) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 4:30 PM ET | Replay |
| Pulse Biosciences (NASDAQ:PLSE) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 4:30 PM ET | Replay |
| Pulse Biosciences (NASDAQ:PLSE) Q1 2026 Earnings Call | Thu, May 07, 2026 · 4:30 PM ET | Replay |
| Pulse Biosciences (NASDAQ:PLSE) Q4 2025 Earnings Call | Thu, Feb 19, 2026 · 4:30 PM ET | Replay |
| Pulse Biosciences (NASDAQ:PLSE) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 4:30 PM ET | Replay |
| Pulse Biosciences (NASDAQ:PLSE) Q2 2025 Earnings Call | Tue, Aug 12, 2025 · 4:30 PM ET | Replay |
| Pulse Biosciences (NASDAQ:PLSE) Q1 2025 Earnings Call | Thu, May 08, 2025 · 4:30 PM ET | Replay |
| Pulse Biosciences (NASDAQ:PLSE) Q4 2024 Earnings Call | Thu, Mar 27, 2025 · 4:30 PM ET | Replay |
| Pulse Biosciences (NASDAQ:PLSE) Q3 2024 Earnings Call | Wed, Oct 30, 2024 · 4:30 PM ET | Replay |
| Pulse Biosciences (NASDAQ:PLSE) Q2 2024 Earnings Call | Mon, Aug 12, 2024 · 4:30 PM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +0.4% |
| Q2 2026 | Aug 6, 2026 · After close | +10.9% |
| Q1 2026 | May 4, 2026 | −10.5% |
| Q4 2025 | Feb 19, 2026 · After close | −14.6% |
| Q3 2025 | Nov 5, 2025 · After close | −3.3% |
| Q2 2025 | Aug 12, 2025 · After close | +11.2% |
| Q1 2025 | May 5, 2025 · Before open | −3.5% |
| Q4 2024 | Mar 26, 2025 · Before open | −0.3% |
| Q3 2024 | Oct 30, 2024 · After close | −1.6% |
| Q2 2024 | Aug 19, 2024 · After close | −3.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | −9.2% |
| Q4 2023 | Mar 28, 2024 · After close | −8.3% |
| Q3 2023 | Nov 13, 2023 · Before open | +4.8% |
| Q2 2023 | Aug 10, 2023 · After close | +5.6% |
| Q1 2023 | May 11, 2023 · After close | +6.3% |
| Q4 2022 | Mar 30, 2023 · After close | +35.5% |
| Q3 2022 | Nov 10, 2022 · After close | −1.9% |
| Q2 2022 | Aug 10, 2022 · After close | +1.8% |
| Q1 2022 | May 11, 2022 · After close | −23.3% |
| Q4 2021 | Mar 31, 2022 · After close | −26.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 15 slides | Aug 6, 2026 |
| Investor Presentation (April 2026) | Investor deck | 14 slides | Apr 25, 2026 |
| Investor Presentation (April 2026) | Investor deck | 18 slides | Apr 16, 2026 |
| Investor Presentation (March 2026) | Investor deck | 16 slides | Mar 3, 2026 |
| Investor Presentation (January 2026) | Investor deck | 17 slides | Jan 14, 2026 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 31 slides | Jan 14, 2025 |
| Investor Presentation (August 2024) | Investor deck | 27 slides | Aug 12, 2024 |
| Investor Presentation (January 2024) | Investor deck | 17 slides | Jan 9, 2024 |
| Investor Presentation (July 2023) | Investor deck | 20 slides | Jul 20, 2023 |
| IPO Roadshow (April 2016) | IPO roadshow | 27 slides | Apr 19, 2016 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| IPO Roadshow (March 2016) | IPO roadshow | 28 slides | Mar 28, 2016 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Tranche closed: US$95.8M raised | Nov 5, 2026 |
| At-the-market programme of common stock Announced: US$75M Use of proceeds: Financing flexibility through key clinical and regulatory milestones | Aug 6, 2026 |
| At-the-market programme of common stock Tranche closed: US$10.7M raised | Aug 6, 2026 |
| Common stock on exercise of warrants Closed: US$1.8M raised | Aug 6, 2026 |
| Warrant exercise of 150% common stock warrants Announced: US$11 a share | Dec 23, 2024 |
| Warrant exercise of warrants exercised for common stock Closed: US$58.4M raised Buyers: Robert W. Duggan (exercised all warrants, corresponding to $58.4 million and 5,306,156 shares) Insiders: Co-Chairman and majority shareholder Robert W. Duggan exercised all of the warrants he acquired in the 2024 rights offering | Dec 19, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$4.00 a share on May 17, 2016.
- Price
- US$4.00 a share
- Shares offered
- 5,000,000 shares of common stock
- Offering size
- US$20 million · Shares offered times the price, worked out by 6ix
- Underwriters
- MDB Capital Group, LLC, Feltl and Company · In the order on the cover
- Shares delivered
- On or about May 23, 2016
Steps
| Step | When |
|---|---|
| Filed publicly | Dec 22, 2015 |
| Amended 3 times | Newest May 3, 2016 |
| Shares registered with an exchange | Apr 15, 2016 |
| Declared effective by the SEC | May 13, 2016 |
| Final prospectus, with the price | May 17, 2016 |
Filings
| Filing | Filed |
|---|---|
| CERTNAS · Nasdaq's certificate of listing | May 18, 2016 |
| 424B3 · Prospectus | May 17, 2016 |
| EFFECT · Notice that a registration is effective | May 13, 2016 |
| CORRESP · Letter to the SEC | May 10, 2016 |
| CORRESP · Letter to the SEC | May 10, 2016 |
| CORRESP · Letter to the SEC | May 10, 2016 |
| S-1/A · Registration statement, amended | May 3, 2016 |
| FWP · Free writing prospectus | Apr 19, 2016 |
| UPLOAD · Letter from the SEC | Apr 18, 2016 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 15, 2016 |
All 18 filings
| Filing | Filed |
|---|---|
| FWP · Free writing prospectus | Mar 28, 2016 |
| CORRESP · Letter to the SEC | Mar 28, 2016 |
| S-1/A · Registration statement, amended | Mar 28, 2016 |
| UPLOAD · Letter from the SEC | Mar 22, 2016 |
| CORRESP · Letter to the SEC | Mar 7, 2016 |
| S-1/A · Registration statement, amended | Mar 7, 2016 |
| UPLOAD · Letter from the SEC | Jan 19, 2016 |
| S-1 · Registration statement | Dec 22, 2015 |
Open IPO · From the cover of the final prospectus (424B3) filed May 17, 2016
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 350.0K | 0 | 0 | 700.0K | 1.42M | 0 | 0 | 0 | 247.0K | 68.0K |
| Cost of revenue | 539.0K | 0 | 0 | 11.9M | 1.97M | 0 | 600.0K | 600.0K | 800.0K | 500.0K |
| Gross profit | -1.26M | -1.18M | -1.21M | -11.2M | -550.0K | -1.09M | -666.0K | -665.0K | -665.0K | -665.0K |
| Research and development | 44.7M | 32.3M | 27.8M | 20.8M | 28.6M | 26.4M | 25.0M | 17.3M | 9.65M | 5.51M |
| Selling, general and administrative | 32.0M | 23.9M | 15.8M | 14.0M | 19.1M | 22.9M | 22.3M | 20.0M | 15.5M | 2.93M |
| Operating income | -76.9M | -56.3M | -43.6M | -58.1M | -63.0M | -50.0M | -48.0M | -37.5M | -25.6M | -9.52M |
| Depreciation and amortization | 406.0K | 512.0K | 542.0K | 690.0K | 480.0K | 430.0K | 494.0K | 645.0K | 336.0K | 94.0K |
| EBITDA | -76.5M | -55.7M | -43.0M | -57.4M | -62.5M | -49.5M | -47.5M | -36.9M | -25.2M | -9.42M |
| Interest expense | 1.10M | 448.0K | 646.0K | 0 | 0 | 0 | 0 | 0 | ||
| Income before tax | 72.8M | 53.6M | -42.2M | -58.5M | -63.7M | -49.9M | -47.0M | -37.5M | -25.6M | -9.52M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | -983.0K | -28.0K | -912.0K | -94.0K |
| Net income | -72.8M | -53.6M | -42.2M | -58.5M | -63.7M | -49.9M | -47.0M | -37.5M | -25.6M | -9.52M |
| Earnings per share, basic | -1.08 | -0.92 | -0.85 | -1.72 | -2.28 | -2.14 | -2.26 | -2.20 | -1.73 | -0.86 |
| Earnings per share, diluted | -2.28 | -2.14 | -2.26 | -2.20 | -1.73 | -0.86 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 80.7M | 118.0M | 44.4M | 61.1M | 44.4M | 12.5M | 6.90M | 51.1M | 3.39M | 2.09M |
| Short-term investments | 0 | 8.01M | 18.5M | 8.48M | 34.7M | 14.3M | ||||
| Receivables | 274.0K | 0 | 0 | 61.0K | 0 | |||||
| Inventory | 136.0K | 0 | 0 | 5.82M | 0 | 0 | 0 | |||
| Current assets | 83.4M | 119.4M | 45.3M | 62.1M | 45.3M | 22.3M | 26.4M | 60.4M | 38.5M | 16.7M |
| Property, plant and equipment | 1.05M | 1.16M | 1.53M | 1.96M | 1.53M | 2.48M | 2.57M | 2.17M | 2.57M | 317.0K |
| Goodwill | 2.79M | 2.79M | 2.79M | 2.79M | 2.79M | 2.79M | 2.79M | 2.79M | 2.79M | 2.79M |
| Total assets | 94.5M | 132.5M | 59.2M | 77.9M | 59.2M | 41.3M | 41.9M | 70.6M | 49.8M | 26.3M |
| Accounts payable | 2.78M | 1.67M | 1.84M | 1.57M | 1.84M | 1.72M | 1.96M | 1.27M | 782.0K | 265.0K |
| Current liabilities | 7.92M | 10.1M | 6.71M | 5.98M | 6.71M | 7.58M | 4.46M | 3.11M | 2.21M | 1.02M |
| Long-term debt | 65.0M | 0 | 0 | |||||||
| Total debt | 7.53M | 8.90M | 9.14M | 76.0M | 11.3M | 11.4M | 6.72M | |||
| Total liabilities | 13.9M | 17.6M | 14.8M | 80.1M | 14.8M | 18.4M | 11.2M | 4.31M | 3.83M | 1.02M |
| Shareholders' equity | 80.7M | 114.9M | 44.4M | -2.25M | 44.4M | 22.9M | 30.7M | 66.3M | 46.0M | 25.3M |
| Shares outstanding | 67.8M | 65.9M | 55.1M | 37.2M | 55.1M | 25.6M | 20.8M | 20.6M | 16.8M | 13.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -54.1M | -36.3M | -33.0M | -47.0M | -54.1M | -35.4M | -34.2M | -23.9M | -11.1M | -8.05M |
| Capital spending | -315.0K | -125.0K | -121.0K | -401.0K | -437.0K | -441.0K | -608.0K | -276.0K | -2.55M | -64.0K |
| Free cash flow | -54.4M | -36.5M | -33.2M | -47.4M | -54.5M | -35.8M | -34.8M | -24.2M | -13.6M | -8.12M |
| Cash from investing | -335.0K | -125.0K | -121.0K | -401.0K | 7.56M | 10.0M | -10.1M | 26.1M | -23.0M | -14.4M |
| Cash from financing | 17.2M | 110.1M | 16.4M | 79.9M | 62.7M | 30.9M | 82.0K | 45.5M | 35.4M | 20.9M |
| Dividends paid | -810.0K | -619.0K | 0 | 0 | ||||||
| Share buybacks | 586.0K | 478.0K | 395.0K | 486.0K | 810.0K | 490.0K | -613.0K | -115.0K | 35.4M | 20.9M |
| Change in cash | -37.3M | 73.7M | -16.8M | 32.5M | 16.2M | 5.56M | -44.2M | 47.7M | 1.30M | -1.52M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 8-K · Current report | Oct 14, 2026 | Current report | SEC |
| 8-K · Current report | Oct 7, 2026 | Current report | SEC |
| 8-K · Current report | Sep 15, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Sep 15, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 6, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Aug 6, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 8-K · Current report | Jul 29, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 10, 2026 | Current report | SEC |
| 4/A · Change in ownership, amended | May 15, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| DEF 14A · Proxy statement | May 11, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 6, 2026 | Current report | SEC |
| 8-K · Current report | May 4, 2026 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2026 | Annual report | SEC |
| 8-K · Current report | Apr 27, 2026 | Current report | SEC |
| 8-K · Current report | Apr 16, 2026 | Current report | SEC |
| 8-K · Current report | Apr 9, 2026 | Management or board change | SEC |
| 8-K · Current report | Apr 7, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 27, 2026 | Management or board change | SEC |
| 8-K · Current report | Mar 17, 2026 | Current report | SEC |
| 8-K · Current report | Mar 12, 2026 | Current report | SEC |
| 8-K · Current report | Mar 9, 2026 | Current report | SEC |
| 8-K · Current report | Mar 3, 2026 | Current report | SEC |
| 8-K/A · Current report, amended | Mar 2, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Mar 2, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 27, 2026 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Feb 25, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 19, 2026 | Results | SEC |
| S-3 · Registration statement | Feb 19, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 19, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Feb 19, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 19, 2026 | Material contract | SEC |
| 10-K · Annual report | Feb 19, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 5, 2026 | Current report | SEC |
| 8-K · Current report | Jan 14, 2026 | Current report | SEC |
| 8-K · Current report | Jan 9, 2026 | Management or board change | SEC |
| 8-K · Current report | Dec 18, 2025 | Current report | SEC |
| 8-K · Current report | Dec 12, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Dec 9, 2025 | Current report | SEC |
| 8-K · Current report | Nov 13, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| DEF 14A · Proxy statement | Oct 28, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Oct 27, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 24, 2025 | Current report | SEC |
| 8-K · Current report | Oct 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 1, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 8, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Sep 2, 2025 | Meeting notice | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| 8-K · Current report | Aug 26, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Aug 18, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 14, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 12, 2025 | Other filings | SEC |
| SD · Specialized disclosure | May 30, 2025 | ESG report | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2025 | Annual report | SEC |
| 10-K · Annual report | Mar 28, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 4, 2025 | Management or board change | SEC |
| 8-K · Current report | Jan 23, 2025 | Current report | SEC |
| 8-K · Current report | Jan 14, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 23, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 19, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 6, 2024 | Management or board change | SEC |
| 8-K · Current report | Nov 26, 2024 | Current report | SEC |
| 8-K · Current report | Oct 31, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Oct 30, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2024 | Results | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 19, 2024 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 15, 2024 | Explanation request | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2024 | Current report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 8-K · Current report | Aug 8, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 15, 2024 | Results | SEC |
| 424B5 · Prospectus | Jul 15, 2024 | Offer document | SEC |
| S-3MEF | Jul 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 8, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jul 3, 2024 | Current report | SEC |
| 8-K · Current report | Jun 28, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2024 | Management or board change | SEC |
| 424B2 · Prospectus | Jun 4, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 4, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 3, 2024 | Other filings | SEC |
| SD · Specialized disclosure | May 31, 2024 | ESG report | SEC |
| POS AM · Amendment to an effective registration | May 28, 2024 | Offer document | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 22, 2024 | Insider trade | SEC |
| 8-K · Current report | May 20, 2024 | Current report | SEC |
| 8-K · Current report | May 15, 2024 | Management or board change | SEC |
| 8-K · Current report | May 9, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | May 6, 2024 | Other filings | SEC |
| 8-K · Current report | May 2, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | May 1, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Apr 30, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 30, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Apr 25, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 25, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 24, 2024 | Other filings | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2024 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Apr 23, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Apr 23, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 18, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 15, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Apr 15, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 10, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 4, 2024 | Other filings | SEC |
| S-3 · Registration statement | Apr 3, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 3, 2024 | Other filings | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| S-3 · Registration statement | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2024 | Current report | SEC |
| 8-K · Current report | Feb 14, 2024 | Current report | SEC |
| 8-K · Current report | Jan 9, 2024 | Current report | SEC |
| 8-K · Current report | Jan 2, 2024 | Current report | SEC |
| 8-K · Current report | Dec 22, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Dec 20, 2023 | Current report | SEC |
| 4 · Change in ownership | Dec 14, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 14, 2023 | Big-stake notice | SEC |
This page holds 200 of 642 filings. Open Filings
Cap table
Built by 6ix from Pulse Biosciences, Inc’s releases · as of Nov 19, 2026
- Common shares
- 73,548,924
- Fully diluted
- 73,555,224
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 73,548,924 | Nov 2, 2026 |
| Options and RSUs | 6,300 | Nov 19, 2026 |
Warrants and options
| Lot |
|---|
| Stock options · US$44.41 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 73,548,924 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Maria Sainz Other companies: Hyperfine, Inc. (President and CEO · Since at least Dec 22, 2021); ATRION Corporation (Director · Aug 30, 2021 – May 24, 2022 · Past); Shockwave Medical Inc (Director · Jul 16, 2020 – May 31, 2024 · Past); Avanos Medical, Inc. (Director · Jan 2, 2019 – Jan 3, 2022 · Past); IRIDEX Corporation (Director · Apr 13, 2018 – Jul 23, 2019 · Past); Halyard Health Inc (Director · Feb 2, 2015 – May 3, 2018 · Past); ClearPoint Neuro Inc. (Director · Jan 1, 2014 – Mar 30, 2018 · Past); The Spectranetics Corp (Director · Nov 1, 2010 – Aug 9, 2017 · Past); Orthofix Medical Inc. (Director · Jun 19, 2008 – Jun 8, 2020 · Past) | Board Member · Since at least Jan 8, 2026 |
| Manmeet Soni Other companies: Summit Therapeutics Inc. (Chief Operating Officer, Chief Financial Officer & Director · Since at least Sep 18, 2020); Reata Pharmaceuticals Inc (COO, CFO and President · Aug 28, 2019 – Sep 26, 2023 · Past); Arena Pharmaceuticals Inc (Director · Dec 14, 2018 – Jun 17, 2020 · Past); Alnylam Pharmaceuticals, Inc. (Chief Financial Officer · May 9, 2017 – Feb 28, 2019 · Past); Ariad Pharmaceuticals Inc (EVP, CFO & Treasurer · Mar 21, 2016 – Feb 16, 2017 · Past); Pharmacyclics Inc (Chief Financial Officer · Feb 13, 2013 – May 26, 2015 · Past) | Director · Since at least Nov 2, 2017 |
| Paul A. LaViolette Other companies: Edwards Lifesciences Corporation (Director · Since at least Jul 13, 2020); Misonix Inc (Director · Sep 27, 2019 – Oct 29, 2021 · Past); Asensus Surgical Inc (Director · Sep 3, 2013 – Jun 30, 2021 · Past); Conceptus Inc (Director · Dec 31, 2008 – Jun 5, 2013 · Past); Baxano Surgical Inc (Director · Aug 7, 2008 – Apr 17, 2014 · Past); Boston Scientific Corporation (COO · Apr 26, 2007 – Jul 1, 2008 · Past) | Chief Executive Officer, Director · Since at least Aug 9, 2024 |
| Sandra A Gardiner Other companies: Adagio Medical Holdings, Inc (Director · Since at least Jul 31, 2024); Kronos Bio Inc (Interim CFO · Sep 15, 2023 – Sep 15, 2023 · Past); Nektar Therapeutics (Chief Financial Officer · Apr 17, 2023 – Apr 17, 2023 · Past); Anebulo Pharmaceuticals, Inc. (Acting Chief Financial Officer · Mar 2, 2023 – Mar 2, 2023 · Past); Lucira Health Inc (Director · Feb 4, 2021 – Jun 1, 2022 · Past) | CFO & EVP Admin. and Finance · Dec 9, 2020 – Dec 14, 2021 · Past |
| Richard A. van den Broek Other companies: Corvus Pharmaceuticals, Inc. (Board Member · Since at least Apr 8, 2025); PhaseBio Pharmaceuticals Inc (Director · Feb 27, 2019 – May 19, 2023 · Past); Celldex Therapeutics, Inc. (Director · Dec 17, 2014 – Jun 8, 2016 · Past); Pharmacyclics Inc (Director · Oct 3, 2011 – May 26, 2015 · Past) | Director · Since at least Aug 6, 2020 |
| Laureen Debuono Other companies: Rani Therapeutics Holdings, Inc. (Director · Jul 29, 2021 – Dec 16, 2024 · Past); Turtle Beach Corporation (Director · Jan 15, 2014 – Feb 3, 2017 · Past); Cadence Pharmaceuticals Inc (Director · Aug 14, 2013 – Mar 19, 2014 · Past) | Director · Oct 4, 2021 – Oct 4, 2021 · Past |
| Brian B Dow Other companies: ProSomnus, Inc. (CHIEF FINANCIAL OFFICER · Mar 1, 2023 – Feb 15, 2024 · Past); Pacific Biosciences of California, Inc. (VP and PAO · Oct 26, 2010 – Mar 2, 2015 · Past) | CFO & SVP Admin. and Finance · May 13, 2016 – May 16, 2017 · Past |
| Kenneth A. Clark Other companies: Summit Therapeutics Inc. (Lead Independent Director · Since at least Oct 7, 2021); Pharmacyclics Inc (Director · Nov 9, 2012 – May 26, 2015 · Past) | Director · Nov 2, 2017 – May 20, 2021 · Past |
| Mahkam Zanganeh Other companies: Summit Therapeutics Inc. (Co-Chief Executive Officer, Director · Since at least Nov 11, 2020) | Director · Since at least Jan 8, 2021 |
| Steven Weber Other companies: IGM Biosciences Inc (PRINCIPAL ACCOUNTING OFFICER · Since at least May 25, 2022) | Principal Accounting Officer · Since at least Jul 14, 2025 |
All 18 people
| Person | Seat |
|---|---|
| Darrin Uecker | Chief Technology Officer, Director · Since at least Jun 1, 2018 |
| David Kenigsberg | Chief Medical Officer of Electrophysiology · Since at least Oct 7, 2026 |
| Ed Ebbers | EVP & GM, Dermatology · Jan 11, 2019 – Jun 1, 2021 · Past |
| Jon Skinner | Chief Financial Officer · Since at least Aug 28, 2026 |
| Kevin Danahy | President and Chief Executive Officer · Since at least Feb 14, 2022 |
| Liane Teplitsky | Chief Operating Officer · Since at least Apr 8, 2026 |
| Mitchell E Levinson | Chief Strategy Officer · May 13, 2016 – Sep 24, 2024 · Past |
| Niv Ad | Chief Science Officer, Cardiac Surgery · Since at least Oct 24, 2025 |
Log in to ask 6ix AI your own questions about Pulse Biosciences, Inc.